Author Description

Cellular blood components contain variable numbers of donor leukocytes. The transfusion of leukocytes accompanying erythrocyte and platelet transfusion may be associated with a variety of potentially harmful effects in the recipient. These adverse effects can largely be avoided by removing leukocytes from blood components to a sufficient degree. This volume, written by leading authorities in the field, provides a timely and comprehensive collection of reviews on the preparation, quality assurance and clinical use of leukocyte-depleted blood products. The most recent information on the adverse effects of leukocytes following blood transfusion is presented, and the effectiveness of methods to prevent or minimize these events by leukocyte depletion is carefully evaluated. Attention is also given to unresolved and controversial issues, such as quality control and cost-efficiency, bringing out the variety of opinions held on these subjects.